海量文库 文档专家
当前位置:首页 >> 医药卫生 >>

histone modification

Oncogene (2011) 30, 3391–3403

& 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11


Histone onco-modi?cations
J Fullgrabe, E Kavanagh and B Joseph ¨
Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden

Post-translational modi?cation of histones provides an important regulatory platform for processes such as gene expression, DNA replication and repair, chromosome condensation and segregation and apoptosis. Disruption of these processes has been linked to the multistep process of carcinogenesis. We review the aberrant covalent histone modi?cations observed in cancer, and discuss how these epigenetic changes, caused by alterations in histonemodifying enzymes, can contribute to the development of a variety of human cancers. As a conclusion, a new terminology ‘histone onco-modi?cations’ is proposed to describe post-translational modi?cations of histones, which have been linked to cancer. This new term would take into account the active contribution and importance of these histone modi?cations in the development and progression of cancer. Oncogene (2011) 30, 3391–3403; doi:10.1038/onc.2011.121; published online 25 April 2011 Keywords: histone modi?cation; histone-modifying enzymes; carcinogenesis; acetylation; methylation

Introduction The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. Epigenetics is de?ned as stably heritable changes in gene expression that are not due to any alteration in the DNA sequence (Berger et al., 2009). The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modi?cations, microRNA expression and nucleosome positioning has revealed a plethora of events that contribute to the neoplastic phenotype. In this review, we summarize the current state of knowledge regarding the status of histone modi?cations and associated histone-modifying enzymes in cancer cells. We discuss how covalent histone modi?cations can be associated with cancer initiation and progression. Histones are the chief protein components of chromatin, acting as spools around which DNA winds
Correspondence: Dr B Joseph, Department of Oncology-Pathology, Karolinska Institutet, Cancer Centrum Karolinska, R8:03, Stockholm171 76, Sweden. E-mail: Bertrand.joseph@ki.se Received 20 February 2011; revised and accepted 11 March 2011; published online 25 April 2011

(Luger et al., 1997). In eukaryotes, an octamer of histones-2 copies of each of the four core histone proteins histone 2A (H2A), histone 2B (H2B), histone 3 (H3) and H4—is wrapped by 147 bp of DNA to form a nucleosome, the fundamental unit of chromatin (Kornberg and Lorch, 1999). Nucleosomal arrays were observed with electron microscopy as a series of ‘beads on a string’, the ‘beads’ being the individual nucleosomes and the ‘string’ being the linker DNA. Linker histones, such as histone H1, and other non-histone proteins can interact with the nucleosomal arrays to further package the nucleosomes to form higher-order chromatin structures (Figure 1a). Histones are no longer considered to be simple ‘DNApackaging’ proteins; they are recognized as being regulators of chromatin dynamics. Histones are subject to a wide variety of post-translational modi?cations including acetylation of lysines and methylation of lysines and arginines as well as serine and threonine phosphorylation, lysine ubiquitylation, glycosylation, sumoylation, adenosine diphosphate ribosylation and carbonylation, all of which are carried out by histonemodifying enzyme complexes in a dynamic manner (Khorasanizadeh, 2004). These modi?cations occur primarily within the histone amino-terminal tails protruding from the surface of the nucleosome as well as on the globular core region (Cosgrove et al., 2004). Histone modi?cations are proposed to affect chromosome function through at least two distinct mechanisms. The ?rst mechanism suggests that modi?cations may alter the electrostatic charge of the histone resulting in a structural change in histones or their binding to DNA. The second mechanism proposes that these modi?cations are binding sites for protein recognition modules, such as the bromodomains or chromodomains, which recognize acetylated lysines or methylated lysines, respectively. For each post-translational modi?cation of histones, enzymes exist which either lay down the appropriate mark or remove it. Major factors in this regulation are the histone acetyltransferases, which acetylate the histone tails and induce chromatin decondensation; histone deacetylases (HDACs), which remove the acetyl groups and promote a tighter binding of histones to DNA; histone methyltransferases (HMTs), which promote or inhibit transcription depending on the target histone residue; and histone demethylases (HDMs), which counteract the HMTs (Allis et al., 2007; Fullgrabe et al., 2010). The histone-modifying enzymes affect histones either locally, through targeted recruitment by

Histone onco-modi?cations J Fullgrabe et al ¨

histone tail Linker DNA

H2B H2A H4 H3 H2B H2A H4 H3



octameric histone core nucleosome

histone posttranslational modifications

Ac Ac




H 4 NH2- S G R G K G G K G L G K G G A K R H R K V L
5 8 12 16 20


Ac Me





H 3 NH2-A R T K Q T A R K S T G G K A P R K Q L A T K A A R K S A
4 9 18 27


Me Ac gain

Me Ac loss

Figure 1 Chromatin structure and histone onco-modi?cations. (a) Chromatin is made of repeating units of nucleosomes, which consist of B147 base pairs of DNA wrapped around a histone octamer consisting of two copies each of the core histones H2A, H2B, H3 and H4. Linker histone H1 is positioned on top of the nucleosome core particules stabilizing higher order chromatin structure. The histones are subject to a wide variety of post-translational modi?cations, primarily on their N-terminal tails, but also in their globular core region. (b) Histone onco-modi?cations; post-translation modi?cations on histone tails that occur in cancer cells are represented. The modi?cations shown are discussed in the main text, apart from H4K5ac and H4K8ac (Van Den Broeck et al., 2008). ac, acetylated; me, methylated.

sequence-speci?c transcription factors (Rundlett et al., 1998), or globally throughout the genome in an untargeted manner affecting virtually all nucleosomes (Vogelauer et al., 2000). Such widespread functions that occur independently of apparent sequence-speci?c DNA-binding proteins are referred to as global histone modi?cations. Similar to their targeted effects, the global activity of the histone-modifying enzymes can also modulate gene activity (Vogelauer et al., 2000). Therefore, histones are modi?ed locally and globally through multiple histone-modifying enzymes with different substrate speci?cities, generating hierarchical patterns of modi?cations from single promoters to large regions of chromosomes and even single cells. At last, growing evidence suggests that histone-modifying enzymes are found deregulated in human cancers. In fact, an extensive analysis of expression patterns of histone-modifying enzymes was even able to discriminate between tumor samples and their normal counterparts and cluster the tumor samples according to cell type (Ozdag et al., 2006). This indicates that changes in the expression of histone-modifying enzymes

have important and tumor-speci?c roles in cancer development.

Histone code hypothesis Work on histone modi?cations and regulation of gene expression have coalesced into the ‘histone code’ hypothesis, initially proposed by Strahl and Allis (2000) and Turner (2000), that encapsulates the function of histone modi?cations in chromatin structure and in the regulation of nuclear functions. According to the histone code hypothesis, distinct combinations of covalent posttranslational modi?cations of histones in?uence chromatin structure and lead to varied transcriptional outputs (Strahl and Allis, 2000). The concept was further generalized to the idea that various combinations of histone modi?cations are related to speci?c chromatinrelated functions and processes (Jenuwein and Allis, 2001). As an example, several histone modi?cations have been ?rmly linked to apoptosis-induced chromatin

Histone onco-modi?cations J Fullgrabe et al ¨


changes, providing collective evidence for an ‘apoptotic histone code’ (Fullgrabe et al., 2010).

Away from DNA methylation; closer to histone modi?cation DNA methylation is probably the most intensely studied epigenetic modi?cation and aberrant changes in DNA methylation (global hypomethylation and CpG island hypermethylation) were among the ?rst events to be recognized in cancer. A link between DNA methylation and cancer was established in 1983, when Feinberg and Vogelstein (1983) demonstrated that the genomes of cancer cells are hypomethylated relative to their normal counterparts. Global demethylation in the repetitive regions of the genome early during tumorigenesis might predispose cells to genomic instability and further genetic changes (Robertson, 2005). Aberrant hypermethylation in cancer usually occurs at CpG islands, and the resulting changes in chromatin structure effectively silence transcription. Cancer cells frequently acquire aberrant methylation of multiple tumor-related genes that cooperate to confer a survival advantage to the neoplastic cells (Baylin and Ohm, 2006). Compiling evidence revealed that genes involved in cell-cycle regulation, tumor cell invasion, DNA repair, chromatin remodeling, cell signaling, transcription and apoptosis are aberrantly hypermethylated and silenced in nearly every tumor. DNA methyltransferases are responsible for establishing and maintenance of DNA methylation patterns, which bring stable long-term gene repression. However, it has recently become evident that DNA methylation and histone modi?cation pathways can be dependent on one another, and that this cross-talk can be mediated by biochemical interactions between HMTs and DNA methyltransferases (Tachibana et al., 2008; Cedar and Bergman, 2009; Zhao et al., 2009). Promoter CpG-island hypermethylation in cancer cells is associated to a particular pattern of histone marks including deacetylation of histones H3 and H4, loss of histone H3 lysine trimethylation, and gain of H3K9 methylation and H3K27 trimethylation. Although some studies suggest that DNA methylation patterns guide histone

modi?cations during gene silencing, an increasing number of studies argue that DNA methylation takes its cue primarily from histone modi?cation states (Cedar and Bergman, 2009). Thus, a complex picture is emerging in which an epigenetic cross-talk, the interplay between DNA methylation and histone modi?cation, is involved in the process of gene transcription and aberrant gene silencing in tumors (Vaissiere et al., 2008).

Histone onco-modi?cations and alterations of the histone modifying enzymatic system in cancer Overall, post-translational modi?cations of histones create an epigenetic mechanism for the regulation of a variety of normal and disease-related processes. Thus considering the fundamental roles of histone modi?cations, it is not surprising that aberrations in histone modi?cations are discovered in cancer (Sharma et al., 2010) (Figure 1b). However, only a few of the more than 60 residues of histones in which modi?cations have been described have been linked to cancer until now (Kouzarides, 2007). In addition, several of the histonemodifying enzymes have also been described to be altered in cancer cells (Figure 2).

Acetylation of H4K16 Global loss of acetylation of histone H4 at lysine 16 (H4K16Ac), together with loss of trimethylation of histone H4 at lysine 20 (H4K20me3) has been observed along with DNA hypomethylation at repetitive DNA sequences in various primary tumors and were the ?rst histone marks reported deregulated in cancer cells (Fraga et al., 2005). Unlike most histone modi?cations, H4K16ac is unique for regulating higher-order chromatin structures beyond the level of nucleosomes. Indeed, this single histone modi?cation in?uences functional interactions between histones and the chromatin ?ber, providing a potential mechanism to regulate chromatin folding (Shogren-Knaak et al., 2006; Shogren-Knaak and Peterson, 2006). Loss of this mark leads to a more


UTX JMJD3 hMOF Suv4-20h2



Me K

Me K



Me K


H3 NH2-






-NH2 H4




Figure 2 Histone-modifying enzymes deregulated in cancer. Several histone-modifying enzymes have been shown to be deregulated in cancer cells. Enzymes for the respective histone onco-modi?cations are represented in green when found to be upregulated or in red if reported as downregulated in cancer cells. Fusion proteins found in cancer cells are depicted in black.

Histone onco-modi?cations J Fullgrabe et al ¨


‘relaxed’ chromatin conformation, which might contribute to genome instability. By now, loss of H4K16ac has been reported for several cancer types and was shown to in?uence cancer cell sensitivity to chemotherapy (Elsheikh et al., 2009; Fraga et al., 2005; Hajji et al., 2010). Reduction in H4K16ac correlates with tumor progression (Fraga et al., 2005). hMOF (human orthologue of the Drosophila melanogaster males absent on the ?rst gene) is the major enzyme that acetylates H4K16 (Neal et al., 2000). Unlike most histone acetyltransferases that target multiple sites on histones, hMOF activity is restricted to residue 16 on the histone H4 tail (Taipale et al., 2005; Utley and Cote, 2003). Worth a notice, hMOF expression is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes for the latter a biomarker for clinical outcome (P?ster et al., 2008). hMOF loss of function leads to defects in the cell cycle and genome instability (Taipale et al., 2005). H4K16ac is deacetylated by the NAD-dependent HDAC sirtuin 1 (SIRT1). Increased expression of SIRT1 has been reported in various tumors, and its use as a prognostic indicator has been proposed (Chen et al., 2005; Hida et al., 2007; Huffman et al., 2007). In addition, a gene designated ‘deleted in breast cancer 1’ (DBC1), which encodes a negative regulator of sirtuin 1 (Cha et al., 2009; Jang et al., 2008), also holds signi?cant prognostic value for breast, gastric and lung carcinoma (Cha et al., 2009; Lee et al., 2011).

Di- and trimethylation of H3K4 Di- and trimethylation of histone H3 at lysine 4 (H3K4me2/me3) is associated with transcriptional competence and activation, with the highest levels observed near transcriptional start sites of highly expressed genes (Shi et al., 2004). A decrease of H3K4me2/me3 is observed in a range of neoplastic tissues and may serve as a predictive factor for clinical outcome for some of them (Seligson et al., 2005; Barlesi et al., 2007; Elsheikh et al., 2009; Ellinger et al., 2010; Manuyakorn et al., 2010; Rajendran et al., 2011). In particular, tumor recurrence occurs earlier in low-grade prostate carcinoma patients with low H3K4me2, independently of other clinical and pathologic parameters (Seligson et al., 2005). H3K4 methylation is established by the SET1 and mixed lineage leukemia (MLL) family of HMTs (Ruthenburg et al., 2007) and removed by the lysine-speci?c histone demethylase 1 (LSD1) and jumonji AT-rich interactive domain 1 (JARID1) family of HDMs (Klose and Zhang, 2007). These enzymes show altered activity in cancer. Chromosomal translocations of MLL lead to ectopic expression of various homeotic Hox genes and have a key role in leukemic progression (Krivtsov and Armstrong, 2007). SMYD3, another H3K4 HMT, is highly expressed in cancer and seems to correlate with the development and progression of colorectal, hepatocellular and breast carcinoma (Hamamoto et al., 2004, 2006). Expression levels of LSD1, a HDM which removes H3K4me/me2 marks, are signi?cantly elevated in bladder, lung, colorectal carcinoma and neuroblastoma (Schulte et al., 2009; Hayami et al., 2011). LSD1 expression correlates with adverse outcome and was inversely correlated with differentiation in neuroblastic tumors (Schulte et al., 2009). The JARID1 family of HDMs has the ability to reverse both the H3K4me2 and H3K4me3 modi?cation state. Fusion of RBBP2/JARID1A to nucleoporin-98 has been identi?ed in human leukemia, and was reported to generate potent oncoproteins that arrest hematopoietic differentiation and induce acute myeloid leukemia in rodent models (Wang et al., 2009). PLU-1/JARID1b, which is found upregulated in breast cancer, has an important role in the proliferative capacity of breast cancer cells through repression of tumor suppressor genes, including BRCA1 (Lu et al., 1999; Yamane et al., 2007).

Trimethylation of H4K20 H4K20 methylation is associated with repressed chromatin (Nishioka et al., 2002; Schotta et al., 2004). In particular, H4K20me3 is found in constitutive heterochromatin regions (Kourmouli et al., 2004; Schotta et al., 2004; Gonzalo et al., 2005), and is enriched in regions of the chromatin which contain silenced genes (Henckel et al., 2009; Pauler et al., 2009). Overall, cancer cells exhibit a global decrease in the levels of H4K20me3 (Fraga et al., 2005; Tryndyak et al., 2006; Van Den Broeck et al., 2008). This reduction occurs in repetitive DNA sequences in association with the global loss of DNA methylation and loss of H4K16ac. Loss of H4K20me3 is as well observed in animal models of carcinogenesis (Kovalchuk et al., 2007; Bagnyukova et al., 2008). Moreover and in contrast, the presence of H4K20me3 has been correlated with the local silencing of genes during the development of cancers (Pogribny et al., 2007; Kwon et al., 2010). Methylation of H4K20 is complex and is catalyzed by several HMTs, including Pr-Set7 and Suv4-20 (Suv4-20h1 and Suv4-20h2). The bulk of the monomethylation on H4K20 is catalyzed primarily by Pr-Set7. H4K20me1 serves as a substrate for the Suv4-20 enzymes responsible for H4K20me2/3. A decrease in H4K20me3 levels in various cancer cell types is associated with diminished expression of Suv420h2 (Pogribny et al., 2006; Tryndyak et al., 2006; Van Den Broeck et al., 2008b).

Acetylation/trimethylation of H3K9 Histone H3 lysine 9 trimethylation (H3K9me3) is a crucial epigenetic mark of heterochromatin and has been associated with transcriptional repression. On the other hand, the presence of acetylated H3K9 (H3K9ac) is considered to be a mark of active chromatin preventing the methylation of this residue and thereby found enriched at regions surrounding transcriptional start sites. In prostate and ovarian tumors, decrease of H3K9ac has been linked with tumor progression. In

Histone onco-modi?cations J Fullgrabe et al ¨


fact, the H3K9ac expression level correlates with histological grading and the clinical stage (Bai et al., 2008; Mohamed et al., 2007; Zhen et al., 2010). In agreement, a decrease in H3K9ac is coupled with a poor prognosis for these patients (Seligson et al., 2005; Zhen et al., 2010). In contrast, in hepatocellular carcinoma an increase in H3K9ac levels was reported (Bai et al., 2008). The decrease of H3K9Ac is required for the increase of H3K9me3, and similar to the acetylation status of H3K9, its methylation status has also been linked to cancer. An increase in H3K9 methylation, leading to aberrant gene silencing, has been found in various forms of cancer (Nguyen et al., 2002; Park et al., 2008; Pogribny et al., 2007) and high level of H3K9me3 were associated with poor prognosis in patients with gastric adenocarcinoma (Park et al., 2008). However, deregulation of this double histone mark (H3K9Ac/H3K9me3) in cancer cells is not necessarily associated with bad prognosis. In fact, patients with non-small cell lung adenocarcinoma or astrocytoma, and exhibiting reduced H3K9ac expression level have a better prognosis (Barlesi et al., 2007; Liu et al., 2010a). H3K9me3 deregulation in patients with acute myeloid leukemia, which occurs preferentially as a decrease in H3K9me3 levels at core promoter regions, is also associated with better prognosis (Muller-Tidow et al., 2010). These rather contradicting data suggest that the same histone modi?cation can predict opposite prognosis in different cancer types. Overexpression of G9a, a H3K9 HMT, has been reported in prostate, lung, liver, colon and breast cancers, which is in line with the increased H3K9me3 and loss of its counterpart H3K9ac in many cancers (Huang et al., 2010; Kondo et al., 2007; Kondo et al., 2008). Increased levels of G9a in patients with lung and liver cancer are associated with poor prognosis (Kondo et al., 2007; Kondo et al., 2008; Chen et al., 2010). Surprisingly, expression of GASC1, a H3K9 HDM, is also found ampli?ed in cancers including breast cancer (Cloos et al., 2006; Liu et al., 2009). Thus, both H3K9 HMT and H3K9 HDM are reported to be overexpressed in breast cancer. However, it is worthwhile to notice that these enzymes have different substrate speci?cities; G9a is a H3K9 speci?c dimethyltransferase, whereas GASC1 is mostly active on H3K9me3 (Maze et al., 2010). Thus, it is possible that G9a is more likely to affect gene expression, whereas GASC1 overexpression, on the other hand, will have a role in genomic instability (Chen et al., 2010).

Trimethylation of H3K27 Trimethylation of lysine 27 on histone H3 (H3K27me3), which is set by the Polycomb system, has been implicated in the formation of repressive chromatin domains. H3K27me3 spreads over large regions harboring many target genes and negatively regulates transcription by promoting a compact chromatin structure (Francis et al., 2004; Ringrose et al., 2004). H3K27me3 is frequently associated with gene silencing, especially

the repression of unwanted differentiation programs during lineage speci?cation (Bernstein et al., 2006; Barski et al., 2007; Mikkelsen et al., 2007). In human cancer, H3K27me3 has been evaluated as a prognostic factor in prostate, breast, ovarian, pancreatic and esophageal cancers (Yu et al., 2007; Wei et al., 2008; He et al., 2009; Tzao et al., 2009), however, some of the results are puzzling. The expression levels of H3K27me3 are signi?cantly higher in esophageal cancers and correlate with poor prognosis for patients (He et al., 2009; Tzao et al., 2009). H3K27me3 expression has also a prognostic value for clinical outcome in patients with breast, prostate, ovarian and pancreatic cancers (Wei et al., 2008). However, in these cancer types, patients with low expression of H3K27me3 had signi?cantly shorter overall survival time when compared with those with high H3K27me3 expression. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2, which mediates H3K27me3 (Hansen et al., 2008). Recent studies have showed that overexpression of EZH2 occurred in diverse cancers, including prostate, breast, renal and ovarian cancers, as well as glioblastoma multiforme (Varambally et al., 2002; Kleer et al., 2003; Orzan et al., 2010; Wagener et al., 2010). Overexpression of EZH2 has been associated with the invasion and progression of cancers, especially with the progression of prostate cancer (Yu et al., 2007). Generally, EZH2 overexpression in cancer cells seems to result in an EZH2-dependent increase in H3K27me3. However, Wei et al. (2008) found no association between EZH2 and H3K27me3 expression in breast, ovarian and pancreatic cancers. One explanation for the absence of correlation between EZH2 and H3K27me3 in these cancer types might lie in the H3K27me3 HDMs. H3K27me3 marks are removed by the HDMs JMJD3/KDM6B and UTX (Xiang et al., 2007). Inactivating somatic mutations of UTX were recently reported in a variety of tumors, particularly in multiple myeloma (van Haaften et al., 2009). JMJD3 has also been linked to tumor development. JMJD3 is induced by Epstein–Barr virus and overexpressed in Hodgkin’s lymphoma (Anderton et al., 2011). JMJD3 is also found upregulated in prostate cancer, and its expression is higher in metastatic prostate cancer (Xiang et al., 2007). In addition, inhibition of JMJD3 expression in mouse embryonic ?broblasts results in suppression of p16Ink4a and p19Arf expression and in their immortalization (Agger et al., 2009). Thus, there is now evidence for both increased and decreased activity of enzymes controlling H3K27 methylation in cancer, demonstrating that a precise balance of this methylation is critical for normal cell growth (Martinez-Garcia and Licht, 2010).

Acetylation of H3K56 The unique feature of Histone H3 lysine 56 (H3K56) is its location in the nucleosome. H3K56 localizes at both

Histone onco-modi?cations J Fullgrabe et al ¨


the entry and exit points of a nucleosome, and it has been shown that histone–DNA interactions at the entry and exit points in the nucleosome are weakened by its acetylation (Masumoto et al., 2005). Although some studies have indicated that H3K56 acetylation (H3K56ac) is involved in transcription, several groups have shown that it is also involved in chromatin assembly during DNA replication and repair and contributes to genomic stability (Xu et al., 2005; Ru?ange et al., 2007; Das et al., 2009; Tjeertes et al., 2009; Yuan et al., 2009). The enzymatic machinery involved in its regulation is still controversial. In humans, both CBP/p300 and hGCN5 have been reported to acetylate H3K56 (Das et al., 2009; Tjeertes et al., 2009; Vempati et al., 2010). The mechanism regulating deacetylation of H3K56 is not less controversial; indeed not less than ?ve HDACs: SIRT1, SIRT2, SIRT3, HDAC1 and HDAC2 have been reported to deacetylate H3K56ac in humans (Das et al., 2009; Miller et al., 2010; Vempati et al., 2010; Yuan et al., 2009). Interestingly, analysis of occurrence of H3K56 acetylation using chromatin immunoprecipitation-on-chip revealed its genome-wide spread, affecting genes involved in several pathways that are implicated in tumorigenesis such as cell cycle, DNA damage response, DNA repair and apoptosis (Vempati et al., 2010). Furthermore, increased H3K56ac, as well as upregulated expression of its positive regulator ASF1A, has been observed in many cancers (Das et al., 2009; Tjeertes et al., 2009).

Acetylation of H4K12 Studies have shown that hypoacetylation of histone H4 lysine 12 (H4K12Ac) can be used as predictive biomarkers for cancer recurrence in the prostate (Seligson et al., 2005) and in non-small-cell lung cancer (Barlesi et al., 2007; Van Den Broeck et al., 2008). Global hypoacetylation of H4K12 was even considered to be informative of tumor stage for colorectal cancer (Ashktorab et al., 2009) and H4K12 hypoacetylation can be used as a predictive biomarker for cancer recurrence in the prostate (Seligson et al., 2005).

Histone variants It is not only histone marks but also the incorporation of speci?c histone variants that becomes altered in cancer cells. On angiogenic signaling, histone cell cycle regulation-defective homolog A (HIRA), a histone chaperone, induces the incorporation of lysine 56 acetylated histone H3.3 at the chromatin domain of VEGFR1 (Dutta et al., 2010). On HIRA depletion, the induction of VEGFR1 and other angiogenic genes is impaired. A direct link between histone variant expression and cancer development has recently been drawn by Khare et al. (2011). They showed that during sequential development of hepatocellular carcinoma, H2A and H2A.1 are overexpressed, whereas H2A.2 is decreased. The increased expression of H2A.1 has been linked to hyperproliferation (Khare et al., 2011). In addition, the histone variant macroH2A appears to suppress tumor progression of malignant melanoma through regulation of CDK8 (Kapoor et al., 2010). In fact, knockdown of macroH2A in low malignant melanoma cells increases proliferation and migration in vitro and growth and metastasis in vivo.

Acetylation of H3K18 The H3K18 acetylation (H3K18ac) mark is regarded as a general marker for active transcription. Loss of H3K18ac is correlated with poor prognosis in patients with prostate, pancreatic, lung, breast and kidney cancers (Seligson et al., 2005; Seligson et al., 2009; Elsheikh et al., 2009; Manuyakorn et al., 2010), and tumor grade suggesting loss of this modi?cation is an important event in tumor progression (Elsheikh et al., 2009). Consistent with this observation, the Kurdistani laboratory demonstrated that oncogenic transformation by the adenovirus protein e1a is accompanied by dramatic changes in the genomic location of H3K18 acetylation (Ferrari et al., 2008; Horwitz et al., 2008). In addition, H3K18 hypoacetylation even strongly correlated with an increased risk of tumor recurrence in patients with low-grade prostate cancer (Seligson et al., 2005). However, in contrast to the report that found that lower levels of H3K18ac predicts poor survival, low expression of this histone mark has been associated with a better prognosis for patients with esophageal squamous cell carcinoma or glioblastoma (Liu et al., 2010a; Tzao et al., 2009). This indicates, once again, that one histone modi?cation can predict opposite prognosis in different cancer types and that histone marks may possess tissue-speci?c features.

Consequences of the histone onco-modi?cations Appropriate patterns of DNA methylation and histone modi?cations are required to maintain cell identity and its disturbance can contribute to cancer formation (Fuks, 2005; Figure 3).

Changes in gene expression The regulation of gene expression is generally associated with speci?c modi?cations of histone tails (Turner, 2000; Strahl and Allis, 2000; Jenuwein and Allis, 2001; Turner, 2007). H3K4me3 as well as H3K9ac are generally found in the promoter regions of actively transcribed genes, whereas repressive histone marks, such as H3K27me3, H3K9me3 and H4K20me3, are responsible for transcriptional repression at promoter regions (Fischle et al., 2003; Schotta et al., 2004). It is striking to note that these histone modi?cations, which are believed to be important for gene expression control, have all been

Histone onco-modi?cations J Fullgrabe et al ¨

DNA repair alterations genomic instability aberrant gene expression cell cycle checkpoint alterations

demethylated H3K4 as well as CpG island DNA methylation, all of which are lost in cancer cells (Fournier et al., 2002; Ooi et al., 2007; Henckel et al., 2009).

Cell cycle checkpoint instability
H3K4 H3K9 H3K9 H3K27 H3K56 H4K16 H4K20
Me Me Ac Me Ac Ac Me

Figure 3 Functional consequences of histone onco-modi?cations. Speci?c histone modi?cations, which have been shown to occur in cancer cells, are displayed and their implication in cancer associated processes, such as aberrant gene expression (in green), genomic instability (in purple), DNA repair (in orange) and cell cycle checkpoint alterations (in blue). ac, acetylated; H, histone; K, lysine; me, methylated.

It is crucial that DNA replication takes place only once during the cell cycle, as its deregulation can result in multiple copies of chromosomes in daughter cells. This process is kept under strict control by the cell cycle checkpoints. In this respect it is quite interesting that cdk inhibitors, which are vital cell cycle checkpoint control components, are epigenetically silenced in cancer. In addition, the H3K4 HMT MLL1 has been described to regulate cell cycle checkpoint integrity and its fusion proteins described in several cancers compromise the S-phase checkpoints (Liu et al., 2010b). In addition, PR-Set7 an H4K20me HMT has also been shown to regulate the S-phase checkpoints (Jorgensen et al., 2007). In fact, Pr-Set7-dependent H4K20 methylation during S-phase is an essential posttranslational mechanism that ensures genome replication and stability (Tardat et al., 2007).

Impaired DNA repair found deregulated in cancer cells. In fact, alterations in modi?cations of histones have been linked to deregulated expression of many genes with important roles in cancer (summarized in Table 1). Silencing at heterochromatin causing genomic instability Widespread changes in the histone landscape, which occur independently of apparent sequence-speci?c DNA-binding proteins, are referred to as global histone modi?cations. Similar to their targeted effects, the global activity of the histone-modifying enzymes can modulate gene activity, but in addition, global modi?cations affect constitutively silenced regions of DNA (Vogelauer et al., 2000). A global loss in DNA methylation and repressive histone modi?cations at heterochromatin regions leads to genomic instability. Transposons are mobile DNA segments that can disrupt gene function by inserting in or near genes. Therefore, they are potentially mutagenous pieces of DNA but their mobility is normally kept under tight control using both DNA methylation and H3K9me2/me3 (Ebbs et al., 2005). Loss of these repressive epigenetic markers increases the random translocation of transposon elements, and hastens the onset of cancer. Similarly, through imprinting, entire chromosomes or chromosome sections are kept silenced to ensure appropriate levels of gene transcription. Loss of imprinting is a feature of genomic instability in cancer, which often leads to the silencing of tumor suppressors and overexpression of oncogenes. Imprinted regions are associated with H3K9me3, H4K20me3 and H3K27me3, The faithful replication of DNA and the ability to repair DNA accurately is important for the maintenance of genomic integrity. Exposure to genotoxic agents, results in DNA damage-induced double strand breaks, an overreliance on DNA repair mechanisms, a build-up of mutations and eventually cancer. Histone acetylation also occurs during the DNA damage response, although its role is less well studied than histone phosphorylations or ubiquitylations. H4K16ac has been shown to be required, along with gammaH2AX, for the recruitment of Mdc1, a DNA repair complex adapter protein, to sites of DNA damage (Li et al., 2010). In addition, H3K56ac and H3K9ac have been shown to be downregulated by DNA damage (Tjeertes et al., 2009). However, others have reported rather an accumulation of H3K56ac on DNA damage (Das et al., 2009; Yuan et al., 2009). H4K20me1/2 is recognized by the checkpoint mediator 53BP1, which targets it to sites of DNA damage (Jorgensen et al., 2007). Loss of these histone modi?cations could explain the impaired DNA damage response in cancer cells. However, the involvement of acetylated and methylated histone marks in the DNA damage response is not well de?ned yet and needs further research.

Perspectives We propose the use of a new terminology ‘histone oncomodi?cations’ to describe the covalent post-translational modi?cations of histones which have been linked to cancer. This epigenetic term is built as its genetic

Histone onco-modi?cations J Fullgrabe et al ¨

Table 1 Genes deregulated by post-translational histone modi?cations in cancer

, ,

counterpart ‘onco-gene’. This new term will take into account the active contribution and importance of these histone modi?cations in the development of cancer. Until now, cancer cell epigenetics has essentially been focused on DNA methylation. However, cancer cell speci?c patterns of histone modi?cations can offer an explanation for how cancer cells acquire a DNA methylation pattern distinct from their normal counterpart. Indeed, models have been proposed in which histone modi?cations guide DNA methylating enzymes (Fuks, 2005; Cedar and Bergman, 2009). Consequently, deregulation of histone modifying enzymes can result in the epigenetic silencing of tumor-suppressor genes by the recruitment of DNA methyltransferases. One remarkable example has been exposed in Glioma cells, where the DNA methytransferase 1 (DNMT1) is signi?cantly found overexpressed. Nevertheless, the DNA methyltransferase 1 promoter exhibits no changes in DNA methylation level in the cancer cells. In contrast, a differential histone code with distinct active marks, AcH3, AcH4, and H3k4me2, was detected in tumors, unlike in normal brain tissues, which were found predominantly enriched with repressive marks such as H3K9me2 and H3K27me3 (Rajendran et al., 2011). The exact sequence of events and the interactions between the enzymes controlling DNA methylation and histone modi?cations in cancer remains to be discovered.

Considering the interdependence between the different histone marks, but also their interactions with DNA methylation and non-coding RNAs, the involvement of a large number of histone modi?cations in cancer development is not surprising. For instance, several histone-modifying enzymes, such as HDAC1, which is often found deregulated in cancer, can target and thereby modify several histone residues. Direct physical interactions between histone modifying enzymes have also been established. One example is the complex including MLL1 and hMOF, which combines H3K4 HMT and H4K16 histone acetyltransferase activities and can thereby regulate two histone oncomodi?cations described in this review (Dou et al., 2005). The consequences of histone onco-modi?cations on carcinogenesis are diverse and involve local as well as global effects. Among the global effects, the loss of genomic stability through loss of transposon silencing, cell cycle checkpoint instability and loss of imprinting are major events. DNA repair can also be impaired by an alteration in the histone landscape. Interestingly histone onco-modi?cations have been linked to all hallmarks of cancer described by Hanahan and Weinberg (2000). Thus, a growing number of pro-apoptotic genes have been described to be downregulated by epigenetic gene silencing. In addition, an upregulation in anti-apoptotic proteins has also been described (Hajji

Histone onco-modi?cations J Fullgrabe et al ¨


et al., 2008). Sustained angiogenesis, metastasis and invasion, insensitivity to growth inhibitors, self-suf?ciency in growth signals and limitless replicative potential have been all linked to histone modi?cations described in this review. Considering the contribution of histone onco-modi?cations to the hallmarks of cancer, these histone marks might represent useful prognostic biomarker. In practice, it was established that a lower degree of global levels of histone modi?cations serves as a prognostic marker for poor clinical outcome and an increased risk of tumor recurrence (Kurdistani, 2011). Thus, histone modi?cation patterns, like DNA methylation patterns, can be used as prognostic tool. In addition, because of the reversibility of histone modi?cations, approaches that target histone onco-modi?cation in the treatment of cancer could be the next wave in cancer therapeutics. Several drugs, which target histone-modifying enzymes, are already in the clinic or are undergoing clinical trials (http://www.clinicaltrials.org). As an illustration, suberoylanilide hydroxamic acid (vorinostat), a highly speci?c and potent HDAC inhibitor is approved by FDA for therapy of cutaneous T-cell lymphoma (Mann et al., 2007). However, as HDACs have a huge number of non-histone targets, non-epigenetic effects for the HDAC inhibitors cannot be excluded in their clinical success. The histone onco-modi?cations we described in this review and their roles in carcinogenesis are only the tip of the iceberg. An increasing number of cancer types are tested on a far larger set of possible histone modi?cations and new patterns in the histone landscape are likely to be uncovered in the future. Gaining deeper insights into the causes as well as the consequences of aberrant histone modi?cations will extend our understanding of cancer biology. One of many histone oncomodi?cation candidates could be the acetylation of H2B-K15, which has been found to be a property of non-dying cells. The loss of this histone mark is required for the appearance of the H2B-S14ph apoptotic mark (Ajiro et al., 2010). Therefore, these histone modi?cations might provide an additional link between apoptosis resistance and histone modi?cations. Increasing our knowledge about the complex interplay between the different histone onco-modi?cations, but also their

interactions with DNA methylation and non-coding RNA will create a complex picture of cancer epigenetics, which might explain many environmental effects of carcinogenesis and help in the prognosis and therapy of malignancies. Abbreviations
53BP1, tumor protein p53 binding protein 1; ac, acetylated; ASF1A, anti-silencing function 1 homolog A; BRCA1, breast cancer 1, early onset; CDK8, cyclin dependent kinase 8; ChIP, chromatin immunoprecipitation; CpG, cytosine-phosphateguanine; DBC1, deleted in breast cancer 1; DNMT, DNA methyltransferase; EZH2, Enhancer of zeste homolog 2; GASC1, gene ampli?ed in squamous cell carcinoma 1; H2A, histone 2A; H2B, histone 2B; H3, histone 3; H4, histone 4; HAT, histone acetyltransferase; HDAC, histone deacetylase; HDACI, HDAC inhibitor; HDM, histone demethylase; HIRA, histone cell cycle regulation-defective homolog A; hMOF, human orthologue of the Drosophila melanogaster males absent on the ?rst gene; HMT, histone methyltransferase; JARID1, jumonji AT-rich interactive domain 1; JMJD3, jumonji domain containing 3; K, lysine; me, methylated; LSD1, lysine-speci?c histone demethylase 1; Mdc1, mediator of DNA-damage checkpoint 1; mH2A, macro histone 2A; MLL, mixed lineage leukaemia; S, serine; SIRT1, sirtuin 1; SMYD3, SET and MYND domain-containing protein 3; T, threonine; ub, ubiquitinylated; UTX, ubiquitously transcribed tetratricopeptide repeat, X chromosome; Vegfr1, vascular endothelial growth factor receptor 1.

Con?ict of interest The authors declare no con?ict of interest.
Acknowledgements We apologize to authors whose primary references could not be cited owing to space limitations. JF is supported by a fellowship from Karolinska Institutet Foundations (KID medel). This work was supported by the Swedish Cancer Society, the Swedish Research Council, and the Karolinska Institutet Foundations (KI Cancer).

Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J et al. (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171–1176. Ajiro K, Scoltock AB, Smith LK, Ashasima M, Cidlowski JA. (2010). Reciprocal epigenetic modi?cation of histone H2B occurs in chromatin during apoptosis in vitro and in vivo. Cell Death Differ 17: 984–993. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T et al. (2007). New nomenclature for chromatin-modifying enzymes. Cell 131: 633–636. Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B. (2010). LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene 29: 3691–3702. Anderton JA, Bose S, Vockerodt M, Vrzalikova K, Wei W, Kuo M et al. (2011). The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin’s lymphoma. Oncogene 2011: 17. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M et al. (2009). Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 54: 2109–2117. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB et al. (2003). Histone modi?cations and silencing prior to DNA methylation of a tumor suppressor gene (2010). Cancer Cell 3: 89–95. Bagnyukova TV, Tryndyak VP, Montgomery B, Churchwell MI, Karpf AR, James SR et al. (2008). Genetic and epigenetic changes in

Histone onco-modi?cations J Fullgrabe et al ¨

rat preneoplastic liver tissue induced by 2-acetylamino?uorene. Carcinogenesis 29: 638–646. Bai X, Wu L, Liang T, Liu Z, Li J, Li D et al. (2008). Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 83–91. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P et al. (2007). Global histone modi?cations predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25: 4358–4364. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. (2007). High-resolution pro?ling of histone methylations in the human genome. Cell 129: 823–837. Baylin SB, Ohm JE. (2006). Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107–116. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. (2009). An operational de?nition of epigenetics. Genes Dev 23: 781–783. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315–326. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C et al. (2007). The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21: 525–530. Cedar H, Bergman Y. (2009). Linking DNA methylation and histone modi?cation: patterns and paradigms. Nat Rev Genet 10: 295–304. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS et al. (2009). Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453–4459. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G et al. (2010). H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule EpCAM. Cancer Res 70: 7830–7840. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. (2005). Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53dependent DNA-damage responses. Cell 123: 437–448. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T et al. (2006). The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307–311. Cosgrove MS, Boeke JD, Wolberger C. (2004). Regulated nucleosome mobility and the histone code. Nat Struct Mol Biol 11: 1037–1043. Das C, Lucia MS, Hansen KC, Tyler JK. (2009). CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459: 113–117. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J et al. (2005). Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121: 873–885. Dutta D, Ray S, Home P, Saha B, Wang S, Sheibani N et al. (2010). Regulation of angiogenesis by histone chaperone HIRA-mediated Incorporation of lysine 56-acetylated histone H3.3 at chromatin domains of endothelial genes. J Biol Chem 285: 41567–41577. Ebbs ML, Bartee L, Bender J. (2005). H3 lysine 9 methylation is maintained on a transcribed inverted repeat by combined action of SUVH6 and SUVH4 methyltransferases. Mol Cell Biol 25: 10507–10515. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W et al. (2010). Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 127: 2360–2366. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM et al. (2009). Global histone modi?cations in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69: 3802–3809. Feinberg AP, Vogelstein B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89–92. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. (2008). Epigenetic reprogramming by adenovirus e1a. Science 321: 1086–1088.

Fischle W, Wang Y, Allis CD. (2003). Binary switches and modi?cation cassettes in histone biology and beyond. Nature 425: 475–479. Fournier C, Goto Y, Ballestar E, Delaval K, Hever AM, Esteller M et al. (2002). Allele-speci?c histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J 21: 6560–6570. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400. Francis NJ, Kingston RE, Woodcock CL. (2004). Chromatin compaction by a polycomb group protein complex. Science 306: 1574–1577. Fuks F. (2005). DNA methylation and histone modi?cations: teaming up to silence genes. Curr Opin Genet Dev 15: 490–495. Fullgrabe J, Hajji N, Joseph B. (2010). Cracking the death code: apoptosis-related histone modi?cations. Cell Death Differ 17: 1238–1243. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE et al. (2005). Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol 7: 420–428. Guo J, Cai J, Yu L, Tang H, Chen C, Wang Z. (2011). EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 102: 530–539. Hajji N, Wallenborg K, Vlachos P, Nyman U, Hermanson O, Joseph B. (2008). Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 27: 3134–3144. Hajji N, Wallenborg K, Vlachos P, Fullgrabe J, Hermanson O, Joseph B. (2010). Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene 29: 2192–2204. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M et al. (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731–740. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y et al. (2006). Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97: 113–118. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57–70. Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A et al. (2008). A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 10: 1291–1300. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T et al. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128: 574–586. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY et al. (2009). Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 9: 461. Henckel A, Nakabayashi K, Sanz LA, Feil R, Hata K, Arnaud P. (2009). Histone methylation is mechanistically linked to DNA methylation at imprinting control regions in mammals. Hum Mol Genet 18: 3375–3383. Hida Y, Kubo Y, Murao K, Arase S. (2007). Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease. Arch Dermatol Res 299: 103–106. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. (2008). Adenovirus small e1a alters global patterns of histone modi?cation. Science 321: 1084–1085. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T et al. (2010). G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem 285: 9636–9641. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A et al. (2007). SIRT1 is signi?cantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612–6618.

Histone onco-modi?cations J Fullgrabe et al ¨

Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR et al. (2008). SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32: 1523–1531. Jenuwein T, Allis CD. (2001). Translating the histone code. Science 293: 1074–1080. Jorgensen S, Elvers I, Trelle MB, Menzel T, Eskildsen M, Jensen ON et al. (2007). The histone methyltransferase SET8 is required for Sphase progression. J Cell Biol 179: 1337–1345. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO et al. (2010). The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468: 1105–1109. Kapoor-Vazirani P, Kagey JD, Powell DR, Vertino PM. (2008). Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68: 6810–6821. Khare SP, Sharma A, Deodhar KK, Gupta S. (2011). Overexpression of histone variant H2A 1 and cellular transformation are related in N-nitrosodiethylamine-induced sequential hepatocarcinogenesis. Exp Biol Med (Maywood) 236: 30–35. Khorasanizadeh S. (2004). The nucleosome: from genomic organization to genomic regulation. Cell 116: 259–272. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606–11611. Klose RJ, Zhang Y. (2007). Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8: 307–318. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR et al. (2008). Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One 3: e2037. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y et al. (2007). Alterations of DNA methylation and histone modi?cations contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37: 974–983. Kornberg RD, Lorch Y. (1999). Twenty-?ve years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285–294. Kourmouli N, Jeppesen P, Mahadevhaiah S, Burgoyne P, Wu R, Gilbert DM et al. (2004). Heterochromatin and trimethylated lysine 20 of histone H4 in animals. J Cell Sci 117: 2491–2501. Kouzarides T. (2007). Chromatin modi?cations and their function. Cell 128: 693–705. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F et al. (2007). Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modi?cations and aberrant microRNA expression. Cell Cycle 6: 2010–2018. Krivtsov AV, Armstrong SA. (2007). MLL translocations, histone modi?cations and leukaemia stem-cell development. Nat Rev Cancer 7: 823–833. Kurdistani SK. (2011). Histone modi?cations in cancer biology and prognosis. Prog Drug Res 67: 91–106. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH et al. (2010). Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modi?cations. Carcinogenesis 31: 974–983. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH et al. (2011). Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42: 204–213. Li X, Corsa CA, Pan PW, Wu L, Ferguson D, Yu X et al. (2010). MOF and H4 K16 acetylation play important roles in DNA damage repair by modulating recruitment of DNA damage repair protein Mdc1. Mol Cell Biol 30: 5335–5347. Liu BL, Cheng JX, Zhang X, Wang R, Zhang W, Lin H et al. (2010a). Global histone modi?cation patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev 19: 2888–2896. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP et al. (2009). Genomic ampli?cation and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28: 4491–4500. Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK et al. (2010b). Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467: 343–346. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185–197. Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, MeierEwert S et al. (1999). A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is speci?cally up-regulated in breast cancer. J Biol Chem 274: 15633–15645. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251–260. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. (2007). FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G et al. (2010). Cellular histone modi?cation patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28: 1358–1365. Martinez-Garcia E, Licht JD. (2010). Deregulation of H3K27 methylation in cancer. Nat Genet 42: 100–101. Masumoto H, Hawke D, Kobayashi R, Verreault A. (2005). A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436: 294–298. Maze I, Covington III HE, Dietz DM, LaPlant Q, Renthal W, Russo SJ et al. (2010). Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 327: 213–216. Michaud-Levesque J, Richard S. (2009). Thrombospondin-1 is a transcriptional repression target of PRMT6. J Biol Chem 284: 21338–21346. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553–560. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S et al. (2010). Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17: 1144–1151. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R et al. (2007). Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int 99: 908–915. Muller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N et al. (2010). Pro?ling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 116: 3564–3571. Neal KC, Pannuti A, Smith ER, Lucchesi JC. (2000). A new human member of the MYST family of histone acetyl transferases with high sequence similarity to Drosophila MOF. Biochim Biophys Acta 1490: 170–174. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G et al. (2002). Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2’-deoxycytidine. Cancer Res 62: 6456–6461. Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y et al. (2002). PR-Set7 is a nucleosome-speci?c methyltransferase that modi?es lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell 9: 1201–1213. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z et al. (2007). DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714–717. Orzan F, Pellegatta S, Poliani L, Pisati F, Caldera V, Menghi F et al. (2010). Enhancer of zeste 2 (Ezh2) is up-regulated in malignant

Histone onco-modi?cations J Fullgrabe et al ¨

gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2010: 1365–2990. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L et al. (2006). Differential expression of selected histone modi?er genes in human solid cancers. BMC Genomics 7: 90. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. (2008). The global histone modi?cation pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15: 1968–1976. Pauler FM, Sloane MA, Huang R, Regha K, Koerner MV, Tamir I et al. (2009). H3K27me3 forms BLOCs over silent genes and intergenic regions and speci?es a histone banding pattern on a mouse autosomal chromosome. Genome Res 19: 221–233. P?ster S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C et al. (2008). The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 122: 1207–1213. Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, Karpinets TV. (2006). Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl de?ciency in rats. Carcinogenesis 27: 1180–1186. Pogribny IP, Tryndyak VP, Muskhelishvili L, Rusyn I, Ross SA. (2007). Methyl de?ciency, alterations in global histone modi?cations, and carcinogenesis. J Nutr 137: 216S–222S. Rajendran G, Shanmuganandam K, Bendre A, Mujumdar D, Goel A, Shiras A. (2011). Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol 2011: 13. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF et al. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31: 1576–1583. Ren TN, Wang JS, He YM, Xu CL, Wang SZ, Xi T. (2010). Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells. Med Oncol (e-pub ahead of print). Ringrose L, Ehret H, Paro R. (2004). Distinct contributions of histone H3 lysine 9 and 27 methylation to locus-speci?c stability of polycomb complexes. Mol Cell 16: 641–653. Robertson KD. (2005). DNA methylation and human disease. Nat Rev Genet 6: 597–610. Ru?ange A, Jacques PE, Bhat W, Robert F, Nourani A. (2007). Genome-wide replication-independent histone H3 exchange occurs predominantly at promoters and implicates H3 K56 acetylation and Asf1. Mol Cell 27: 393–405. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M. (1998). Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 392: 831–835. Ruthenburg AJ, Allis CD, Wysocka J. (2007). Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25: 15–30. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G et al. (2004). A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18: 1251–1262. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. (2009). Lysine-speci?c demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69: 2065–2071. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S et al. (2009). Global levels of histone modi?cations predict prognosis in different cancers. Am J Pathol 174: 1619–1628. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. (2005). Global histone modi?cation patterns predict risk of prostate cancer recurrence. Nature 435: 1262–1266. Sharma S, Kelly TK, Jones PA. (2010). Epigenetics in cancer. Carcinogenesis 31: 27–36. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. (2008). EZH1 mediates methylation on histone H3 lysine 27 and

complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32: 491–502. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941–953. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311: 844–847. Shogren-Knaak M, Peterson CL. (2006). Switching on chromatin: mechanistic role of histone H4-K16 acetylation. Cell Cycle 5: 1361–1365. Strahl BD, Allis CD. (2000). The language of covalent histone modi?cations. Nature 403: 41–45. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y. (2008). G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J 27: 2681–2690. Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A et al. (2005). hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 25: 6798–6810. Tardat M, Murr R, Herceg Z, Sardet C, Julien E. (2007). PR-Set7dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol 179: 1413–1426. Tjeertes JV, Miller KM, Jackson SP. (2009). Screen for DNA-damageresponsive histone modi?cations identi?es H3K9Ac and H3K56Ac in human cells. EMBO J 28: 1878–1889. Tryndyak VP, Kovalchuk O, Pogribny IP. (2006). Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 5: 65–70. Turner BM. (2000). Histone acetylation and an epigenetic code. Bioessays 22: 836–845. Turner BM. (2007). De?ning an epigenetic code. Nat Cell Biol 9: 2–6. Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH et al. (2009). Prognostic signi?cance of global histone modi?cations in resected squamous cell carcinoma of the esophagus. Mod Pathol 22: 252–260. Utley RT, Cote J. (2003). The MYST family of histone acetyltransferases. Curr Top Microbiol Immunol 274: 203–236. Vaissiere T, Sawan C, Herceg Z. (2008). Epigenetic interplay between histone modi?cations and DNA methylation in gene silencing. Mutat Res 659: 40–48. Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B et al. (2008). Loss of histone H4K20 trimethylation occurs in preneoplasia and in?uences prognosis of non-small cell lung cancer. Clin Cancer Res 14: 7237–7245. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521–523. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, KumarSinha C, Sanda MG et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624–629. Vempati RK, Jayani RS, Notani D, Sengupta A, Galande S, Haldar D. (2010). p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J Biol Chem 285: 28553–28564. Vogelauer M, Wu J, Suka N, Grunstein M. (2000). Global histone acetylation and deacetylation in yeast. Nature 408: 495–498. Wagener N, Macher-Goeppinger S, Pritsch M, Husing J, HoppeSeyler K, Schirmacher P et al. (2010). Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10: 524. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H et al. (2009). Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD ?nger. Nature 459: 847–851. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV et al. (2008). Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor

Histone onco-modi?cations J Fullgrabe et al ¨

outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47: 701–706. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. (2010). Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 17: 801–810. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. (2007). JMJD3 is a histone H3K27 demethylase. Cell Res 17: 850–857. Xu F, Zhang K, Grunstein M. (2005). Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell 121: 375–385. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, ErdjumentBromage H et al. (2007). PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 25: 801–812. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G et al. (2007). A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657–10663. Yuan J, Pu M, Zhang Z, Lou Z. (2009). Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle 8: 1747–1753. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ et al. (2009). PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 16: 304–311. Zhen L, Gui-lan L, Ping Y, Jin H, Ya-li W. (2010). The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical signi?cance. Int J Gynecol Cancer 20: 82–86.


更多搜索:histone modification


参考文献: [1]EspinoPS,DrobicB,DunnKL,DavieJR.Histonemodificationsasaplatformforcancertherapy[J]. JellBiochem,2005,94(9):1088-1102. [2]张海元,刘娟.肿瘤...


The changes of ep igenetics such asDNA methylation and histone modification can regulate the exp ression of genes and p lay an important role in the ...

Epigenetics and health

This modification is either the addition of methyl groups to the DNA or of a cetyl groups tothe histones. 这种改性或者是甲基增至 DNA 中,或者是乙酰基...

遗传学 重点 100713 刘戈飞

②组蛋白修饰 Histone modification/histone variants 中的乙酰化 Acetylation, 影响: 乙酰化 histone acetylation enhances transcription while histone deacetylation ...


Old modification, new functions Modification of ribosomal RNAs by RNA-guided... a Golgi Histone Free Apparatus-anchored Acetyltransferase, Histone H4 and 4...


Studies on chemical structure modification and biology of a natural product, ...Competitive or noncompetitive, that’s the question: research toward histone ...


18 modification 19页 1下载券 MOD法 89页 免费 histone modification 13页 2下载券 2nd Modification 暂无评价 10页 2下载券 喜欢此文档的还喜欢 MOD法标准...


Functional roles of human MRG15 and its homologues in histone modification and transcription regulation 人类肝脏蛋白质组计划专场(一) Human Liver Proteome ...


组蛋白修饰(histone modification) :是指染色质上的组蛋白被甲基化、乙酰化或磷酸化的过程。 组蛋白修饰 2 中心法则( 中心法则(central dogma)F.Crick 于 1958 ...

Mapping methylation

Histone_Methylation 暂无评价 1页 免费 DNA methylation and heal... 9页 2...Analysis of 17 species fills in evolutionary history of DNA modification ...

网站首页 | 网站地图
All rights reserved Powered by 酷我资料网 koorio.com
copyright ©right 2014-2019。